Qiagen (QGEN) Stock Rating Reaffirmed by Commerzbank

Qiagen (NASDAQ:QGEN)‘s stock had its “buy” rating reiterated by investment analysts at Commerzbank in a research report issued to clients and investors on Wednesday.

Other analysts also recently issued reports about the company. TheStreet raised Qiagen from a “c+” rating to a “b+” rating in a research note on Tuesday, November 7th. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a research note on Friday, December 1st. Zacks Investment Research raised Qiagen from a “hold” rating to a “buy” rating and set a $39.00 price objective for the company in a research note on Tuesday, October 10th. Cowen reaffirmed a “hold” rating and set a $34.00 price objective on shares of Qiagen in a research note on Thursday, December 21st. Finally, BidaskClub raised Qiagen from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $34.63.

Qiagen (NASDAQ QGEN) traded up $0.55 on Wednesday, reaching $32.21. The company’s stock had a trading volume of 6,152,400 shares, compared to its average volume of 1,936,667. The company has a current ratio of 5.33, a quick ratio of 4.78 and a debt-to-equity ratio of 0.68. The stock has a market cap of $7,440.00, a P/E ratio of 82.59, a PEG ratio of 1.80 and a beta of 1.10. Qiagen has a 12-month low of $27.51 and a 12-month high of $36.34.

Qiagen (NASDAQ:QGEN) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.32 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.32. The firm had revenue of $364.00 million during the quarter, compared to the consensus estimate of $363.42 million. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. The firm’s revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.29 EPS. analysts predict that Qiagen will post 1.25 earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. Oppenheimer Asset Management Inc. raised its stake in shares of Qiagen by 0.5% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock worth $133,000 after buying an additional 20 shares in the last quarter. M&T Bank Corp raised its stake in shares of Qiagen by 2.7% during the 2nd quarter. M&T Bank Corp now owns 8,155 shares of the company’s stock worth $273,000 after buying an additional 215 shares in the last quarter. Quadrant Capital Group LLC raised its stake in shares of Qiagen by 4.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock worth $183,000 after buying an additional 225 shares in the last quarter. QS Investors LLC raised its stake in shares of Qiagen by 1.7% during the 2nd quarter. QS Investors LLC now owns 13,594 shares of the company’s stock worth $456,000 after buying an additional 226 shares in the last quarter. Finally, Acrospire Investment Management LLC raised its stake in shares of Qiagen by 11.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock worth $112,000 after buying an additional 349 shares in the last quarter. 62.09% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Qiagen (QGEN) Stock Rating Reaffirmed by Commerzbank” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/01/10/qiagen-qgen-stock-rating-reaffirmed-by-commerzbank.html.

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

What are top analysts saying about Qiagen? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Qiagen and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit